Assessing the Effectiveness of Add-On Therapy of Palmitoylethanolamide to Standard Therapy in Diabetic Peripheral Neuropathy
,
Abstract
Background: Diabetic Peripheral Neuropathy (DPN) is a common yet challenging complication of diabetes, particularly in managing neuropathic pain. Palmitoylethanolamide (PEA), a naturally occurring nutraceutical from the ALIAmides group, has demonstrated potential for pain modulation, inflammation reduction, and improving quality of life.
Method: A 9-month prospective observational study at PSG Hospital evaluated the impact of adding oral capsule PEA (708 mg in two divided doses) to standard therapy for DPN patients unresponsive to maximum tolerated dosages of Gabapentin, Pregabalin, amitriptyline, or duloxetine. The outcomes were the pain severity and quality of life. Pain was assessed using the Visual Analog Scale (VAS), sensitivity was evaluated via monofilament testing, and quality of life was measured using the American Chronic Pain Association (ACPA) Quality of Life Scale (QOLS).
Results: Sixty patients with DPN were treated with adjunctive PEA and monitored for 8 weeks. Pain scores decreased significantly (6.05±1.096 to 4.15±1.233 at 4 weeks and 3.57±1.155 at 8 weeks, p˂0.05). Sensitivity improved via monofilament testing (7.12±1.58 to 9.43±0.78). Quality of life scores rose from 7.67 to 9.41 at 4 weeks and 9.68 at 8 weeks, indicating notable benefits.
Conclusion: PEA proved effective as a supplemental treatment for nonresponsive DPN patients, yielding significant reductions in pain, enhanced sensitivity, and better quality of life. Importantly, no side effects were reported, affirming its tolerability and safety.
Alghafri RM, Gatt A, Formosa C. Depression symptoms in patients with diabetic peripheral neuropathy. Rev Diabet Stud. 2020;16(1):35-40.
Pop-Busui R, Ang L, Boulton AJM, et al. Diagnosis and treatment of painful diabetic peripheral neuropathy. Arlington (VA): American Diabetes Association; 2022 Feb. Available from: URL: https://www.ncbi.nlm.nih.gov/books/NBK580224/
Bouhassira D, Attal N, Fermanian J, et al. (2004). Neuropathic Pain Symptom Inventory (NPSI) [Database record]. APA PsycTests.
Picke AK, Campbell G, Napoli N, Hofbauer LC, Rauner M. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocr Connect. 2019;8(3):R55-R70.
Bodman MA and Varacallo M. Peripheral Diabetic Neuropathy. In StatPearls, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Apr. 16, 2024. [Online].
Mu ZP, Wang YG, Li CQ, et al. Association between tumor necrosis factor-α and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis. Mol Neurobiol. 2017;54(2):983-96.
Malik RA. Pathology of human diabetic neuropathy. Handb Clin Neurol. 2014;126:249-59.
Enders J, Elliott D, Wright DE. Emerging nonpharmacologic interventions to treat diabetic peripheral neuropathy. Antioxid Redox Signal. 2023;38(13-15):989-1000.
Hesselink JK. New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. The Open Pain Journal. 2012;5(1):12-23.
LoVerme J, Russo R, Rana GL, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther. 2006;319(3):1051-61.
Landolfo E, Cutuli D, Petrosini L, Caltagirone C. Effects of palmitoylethanolamide on neurodegenerative diseases: a review from rodents to humans. Biomolecules. 2022 5;12(5):667.
Verme JL, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-9.
Darmani NA, Izzo AA, Degenhardt B, et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology. 2005;48(8):1154-63.
Genovese T, Esposito E, Mazzon E, et al. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther. 2008;326(1):12-23.
Naderi N, Majidi M, Mousavi Z, Khoramian Tusi S, Mansouri Z, Khodagholi F. The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats. Neurochem Res. 2012;37(4):778-85.
D'Amico R, Impellizzeri D, Cuzzocrea S, Di Paola R. ALIAmides update: palmitoylethanolamide and its formulations on management of peripheral neuropathic Pain. Int J Mol Sci. 2020;21(15):5330.
Sancho R, Calzado MA, Di Marzo V, Appendino G, Muñoz E. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol Pharmacol. 2003;63(2):429-38.
Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11-24.
Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623.
Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat. 2014;2014:854560.
Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-42.
Lang-Illievich K, Klivinyi C, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H. The effect of palmitoylethanolamide on pain intensity, central and peripheral sensitization, and pain modulation in healthy volunteers-a randomized, double-blinded, placebo-controlled crossover trial. Nutrients. 2022;14(19):4084.
Chaurasia ID, Vinayak K, Tiwari S, Malpani P, Behram S, Koshariya M. Therapeutic benefit of palmitoylethanolamide in the management of neuropathic pain. Romanian Neurosurgery. 2018; 32(4):654–61.
Zhang Q, Yi N, Liu S, et al. Easier operation and similar power of 10 g monofilament test for screening diabetic peripheral neuropathy. J Int Med Res. 2018;46(8):3278-84.
Pickering E, Steels EL, Steadman KJ, Rao A, Vitetta L. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. Inflammopharmacology. 2022;30(6):2063-77.
Magrinelli F, Briani C, Romano M, et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. J Diabetes Res. 2015;2015:547834.
| Files | ||
| Issue | Vol 12, No 4 (Autumn 2024) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v12i4.17454 | |
| Keywords | ||
| Palmitoylethanolamide Peripheral neuropathy Conventional therapy neuroprotective effect Pain. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
